FULC
The headline wasn’t just the earnings number
Fulcrum Therapeutics’ first-quarter call was part earnings update, part biotech pep rally. The company said its Phase 1b Pioneer trial for Posterior Dare in sickle cell disease showed a meaningful jump in fetal hemoglobin and fewer vaso-occlusive crises, which is the kind of thing that can make a small biotech sound a lot less like a science experiment and a lot more like a real shot on goal.
Why the clinical data matters
The company said 20 mg once daily drove HbF from 7.1% at baseline to 19.3% by week 12, with improvements in anemia and hemolysis markers. Even better for the story: 7 of 12 patients had no VOCs during the treatment period, and the drug was generally well tolerated with no treatment-related serious adverse events reported so far.
That matters because sickle cell is a brutal disease with very few great options. If Posterior Dare keeps showing this kind of signal, Fulcrum may have a differentiated oral therapy on its hands — the kind of pipeline asset that can change how investors value a company overnight, or at least give the stock a reason to breathe.
Cash is king, especially in biotech
The earnings side of the call wasn’t flashy, but it did what investors needed: Fulcrum reported a Q1 net loss of $22.2 million and ended the period with $333.3 million in cash and marketable securities. Management says that gives the company runway into 2029, which is biotech speak for “we’re not scrambling for funding tomorrow.”
The next catalyst is already queued up
Fulcrum also said it started an open-label long-term dosing study and enrolled its first patient. The bigger near-term swing factor, though, is the upcoming end-of-phase meeting with the FDA, where the company expects to get more clarity on the next clinical design.
Big picture: Fulcrum didn’t just serve up a quarterly report — it gave investors a reminder that in biotech, data plus cash can be a pretty persuasive combo.